Ellen-Margrethe Hauge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ellen-Margrethe Hauge has a total of 283 co-authors. Here are the top co-authors by number of shared publications:
- Kresten Krarup Keller
Department of Rheumatology Aarhus University Hospital Aarhus Denmark
13 shared publications - Annette de Thurah
Department of Rheumatology Aarhus University Hospital Aarhus Denmark
11 shared publications - Josephine Therkildsen
Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
8 shared publications - Berit Dalsgaard Nielsen
Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Rheumatology, Horsens Regional Hospital, Horsens, Denmark
7 shared publications - Anne Troldborg
Aarhus University Hospital
6 shared publications - Simon Winther
Department of Clinical Medicine, Aarhus University , Aarhus
6 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Oxford University Press (OUP) in Rheumatology
Cost-Effectiveness of Digital Patient Education in Rheumatoid Arthritis: An economic evaluation from a randomised controlled trial
Objective: Self-management support is essential in rheumatoid arthritis (RA). The WebRA trial showed that digital patient education (PE) improves self-efficacy, supports self-management, and reduces outpatient visits. This study assessed the 12-month cost-effectiveness from a partial societal perspective. Methods: Adults newly diagnosed with RA were randomised to digital or face-to-face PE. Quality-adjusted life years (QALYs) were estimated from EQ-5D-5L measurements over 12 months. Costs were obtained from national registries and incremental cost-effectiveness ratios (ICERs) were calculated. The probability of cost-effectiveness was estimated using probabilistic sensitivity analysis. Minimal important change in self-efficacy was the secondary outcome. Results: Baseline characteristics of the 175 participants were balanced (intervention vs control): 60.7% vs 61.5% female, mean age 58 vs 56 years, and mean disease activity score (DAS28) 4.4 vs 4.6. Digital PE led to lower healthcare costs (€9,322 vs €9,886), and minor QALY gains (mean difference 0.013). The intervention was dominant in both adjusted and crude models, with ICERs of -€43,692/QALY and -€24,056/QALY, respectively. In bootstrap analyses, 47.3% (adjusted) and 52.7% (crude) of iterations fell in the south-east quadrant (lower costs, better outcomes). Probability of cost-effectiveness reached 71.5% at a €22,665/QALY threshold. For self-efficacy, digital PE was cost-saving, but effects were small and inconsistent. Conclusions: Digital PE was associated with lower costs and a small QALY gain compared with face-to-face PE, with a moderate probability of cost-effectiveness. Digital PE may be a cost-effective alternative; however, the estimated effects were subject to some uncertainty and sensitivity to model specification. Further investigation in broader populations is warranted.
- 18 November 2026
- Published by Oxford University Press (OUP) in Rheumatology
Open AccessCost-Effectiveness of Digital Patient Education in Rheumatoid Arthritis: An economic evaluation from a randomised controlled trial
Objective: Self-management support is essential in rheumatoid arthritis (RA). The WebRA trial showed that digital patient education (PE) improves self-efficacy, supports self-management, and reduces outpatient visits. This study assessed the 12-month cost-effectiveness from a partial societal perspective. Methods: Adults newly diagnosed with RA were randomised to digital or face-to-face PE. Quality-adjusted life years (QALYs) were estimated from EQ-5D-5L measurements over 12 months. Costs were obtained from national registries and incremental cost-effectiveness ratios (ICERs) were calculated. The probability of cost-effectiveness was estimated using probabilistic sensitivity analysis. Minimal important change in self-efficacy was the secondary outcome. Results: Baseline characteristics of the 175 participants were balanced (intervention vs control): 60.7% vs 61.5% female, mean age 58 vs 56 years, and mean disease activity score (DAS28) 4.4 vs 4.6. Digital PE led to lower healthcare costs (€9,322 vs €9,886), and minor QALY gains (mean difference 0.013). The intervention was dominant in both adjusted and crude models, with ICERs of -€43,692/QALY and -€24,056/QALY, respectively. In bootstrap analyses, 47.3% (adjusted) and 52.7% (crude) of iterations fell in the south-east quadrant (lower costs, better outcomes). Probability of cost-effectiveness reached 71.5% at a €22,665/QALY threshold. For self-efficacy, digital PE was cost-saving, but effects were small and inconsistent. Conclusions: Digital PE was associated with lower costs and a small QALY gain compared with face-to-face PE, with a moderate probability of cost-effectiveness. Digital PE may be a cost-effective alternative; however, the estimated effects were subject to some uncertainty and sensitivity to model specification. Further investigation in broader populations is warranted.
- Open Access
- 27 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (10) , 1406
Heart Failure and Risk Assessment in Systemic Autoimmune Disease: Do Inflammation, Autoantibodies and Sex Matter?
Heart failure (HF) is increasingly recognized as an important cardiovascular complication of systemic autoimmune rheumatic diseases (SARDs), which include rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Sjögren’s syndrome, and idiopathic inflammatory myopathies. Excess HF risk is only partly explained by conventional cardiovascular risk factors and ischemic heart disease. Chronic inflammation, endothelial and coronary microvascular dysfunction, immune-mediated myocardial injury, oxidative stress, fibrosis, and selected autoantibody-associated pathways may contribute to progressive myocardial dysfunction. Biological sex is also relevant because most SARDs predominantly affect women and sex influences immune regulation, vascular biology, myocardial remodeling, and HF phenotype. Current cardiovascular risk scores are primarily designed for atherosclerotic events and incompletely capture autoimmune disease-specific determinants of myocardial injury. This review summarizes HF across major SARDs and examines three interconnected modifiers of myocardial vulnerability—chronic inflammation, autoantibodies, and biological sex. We further discuss how disease activity and duration, biomarkers, global longitudinal strain, cardiovascular magnetic resonance, and conventional risk factors might be integrated into future risk assessment. A biology-centered approach may enable earlier recognition of subclinical myocardial involvement and individualized cardiovascular surveillance, but prospective validation is required before disease-specific HF-screening strategies can be recommended.
- 27 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (10) , 1406
Open AccessHeart Failure and Risk Assessment in Systemic Autoimmune Disease: Do Inflammation, Autoantibodies and Sex Matter?
Heart failure (HF) is increasingly recognized as an important cardiovascular complication of systemic autoimmune rheumatic diseases (SARDs), which include rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Sjögren’s syndrome, and idiopathic inflammatory myopathies. Excess HF risk is only partly explained by conventional cardiovascular risk factors and ischemic heart disease. Chronic inflammation, endothelial and coronary microvascular dysfunction, immune-mediated myocardial injury, oxidative stress, fibrosis, and selected autoantibody-associated pathways may contribute to progressive myocardial dysfunction. Biological sex is also relevant because most SARDs predominantly affect women and sex influences immune regulation, vascular biology, myocardial remodeling, and HF phenotype. Current cardiovascular risk scores are primarily designed for atherosclerotic events and incompletely capture autoimmune disease-specific determinants of myocardial injury. This review summarizes HF across major SARDs and examines three interconnected modifiers of myocardial vulnerability—chronic inflammation, autoantibodies, and biological sex. We further discuss how disease activity and duration, biomarkers, global longitudinal strain, cardiovascular magnetic resonance, and conventional risk factors might be integrated into future risk assessment. A biology-centered approach may enable earlier recognition of subclinical myocardial involvement and individualized cardiovascular surveillance, but prospective validation is required before disease-specific HF-screening strategies can be recommended.
- Open Access
- 23 September 2026
- Published by Wiley in Arthritis & Rheumatology
Incidence and Disease Course of Polymyalgia Rheumatica During Two Decades: A Nationwide Study Across Health Care Sectors in Denmark
Objective: A new algorithm enables the identification of patients with polymyalgia rheumatica (PMR) across health care sectors in Denmark. We estimated annual incidence rates from 2003 to 2024 and described the disease course, including the occurrence of late‐onset giant cell arteritis (GCA) and prednisolone or prednisone (PDN) treatment. Methods: A Danish nationwide, population‐based cohort study was conducted using data linked at the individual level. Cases were identified among people ages 50 years or older between January 1, 2003, and November 1, 2024. Results: A total of 51,401 patients were identified, including 24,456 from primary care and 26,945 from secondary care. The age‐standardized incidence of PMR was 112 per 100,000 people (95% confidence interval [CI] 110.8–112.8). During the study period, the incidence declined by 53% in primary health care and increased by 30% in secondary health care, resulting in an overall decline of 12%. Among patients with PMR, GCA occurred at a rate of 5.4 (95% CI 5.1–5.7) per 1,000 patient‐years, with a median of 68 days (interquartile range 10–602) from PMR diagnosis. Overall, 28% and 22% of patients were still treated with PDN after 5 and 10 years, with a median daily dose of 4.1 and 5.5 mg of PDN, respectively. Conclusion: The increasing incidence of PMR in secondary health care was exceeded by the declining incidence in primary health care. Most late‐onset GCA developed within the first year after PMR diagnosis. Many patients continued treatment with PDN for 5 to 10 years, indicating a need for earlier use of concomitant therapies.
- 23 September 2026
- Published by Wiley in Arthritis & Rheumatology
Open AccessIncidence and Disease Course of Polymyalgia Rheumatica During Two Decades: A Nationwide Study Across Health Care Sectors in Denmark
Objective: A new algorithm enables the identification of patients with polymyalgia rheumatica (PMR) across health care sectors in Denmark. We estimated annual incidence rates from 2003 to 2024 and described the disease course, including the occurrence of late‐onset giant cell arteritis (GCA) and prednisolone or prednisone (PDN) treatment. Methods: A Danish nationwide, population‐based cohort study was conducted using data linked at the individual level. Cases were identified among people ages 50 years or older between January 1, 2003, and November 1, 2024. Results: A total of 51,401 patients were identified, including 24,456 from primary care and 26,945 from secondary care. The age‐standardized incidence of PMR was 112 per 100,000 people (95% confidence interval [CI] 110.8–112.8). During the study period, the incidence declined by 53% in primary health care and increased by 30% in secondary health care, resulting in an overall decline of 12%. Among patients with PMR, GCA occurred at a rate of 5.4 (95% CI 5.1–5.7) per 1,000 patient‐years, with a median of 68 days (interquartile range 10–602) from PMR diagnosis. Overall, 28% and 22% of patients were still treated with PDN after 5 and 10 years, with a median daily dose of 4.1 and 5.5 mg of PDN, respectively. Conclusion: The increasing incidence of PMR in secondary health care was exceeded by the declining incidence in primary health care. Most late‐onset GCA developed within the first year after PMR diagnosis. Many patients continued treatment with PDN for 5 to 10 years, indicating a need for earlier use of concomitant therapies.
- Open Access
- 9 September 2026
- Published by Elsevier in Journal of Autoimmunity
- Vol. 164, 103615
Disease-activity-linked complement-coagulation interactions and persistent platelet activation in treatment-naïve systemic lupus erythematosus
- 9 September 2026
- Published by Elsevier in Journal of Autoimmunity
- Vol. 164, 103615
Open AccessDisease-activity-linked complement-coagulation interactions and persistent platelet activation in treatment-naïve systemic lupus erythematosus
- Open Access
- 31 August 2026
- Published by Springer Nature in Journal of Cannabis Research
Cannabidiol for chronic pain in rheumatoid arthritis and ankylosing spondylitis: a randomized, placebo-controlled trial with exploratory tetrahydrocannabinol add-on
Background: Persistent chronic pain remains a major unmet need in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS), even when inflammatory disease activity is low. Evidence for cannabinoid-based treatment in inflammatory rheumatic disease is limited. We investigated the efficacy and safety of low-dose cannabidiol (CBD) for chronic pain in RA and AS and explored the effects of adjunctive tetrahydrocannabinol (THC) in non-responders. Methods: In this multicentre, double-blind, randomized, placebo-controlled trial, 66 patients with RA or AS and persistent pain despite low inflammatory disease activity were randomized 1:1 to oral CBD or placebo for 12 weeks. The primary endpoint was a reduction of at least 20 points on the pain visual analogue scale (VAS) at week 12. After the blinded phase, non-responders entered a 12-week open-label phase: non-responders in the placebo group switched to CBD, while non-responders in the CBD group received add-on THC. Secondary outcomes included continuous pain VAS, sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI), cognitive performance assessed by the Trail Making Test (TMT) and Digit Symbol Substitution Test (DSST), disease activity measures, and safety. Results: At week 12, the primary endpoint was achieved by 9/32 patients (28%) receiving placebo and 3/30 patients (10%) receiving low-dose CBD. Low-dose CBD did not demonstrate superior pain relief compared with placebo and was associated with poorer sleep quality, while no significant between-group differences were observed for cognitive outcomes or inflammatory markers. In the exploratory open-label phase, 9/23 patients (39%) receiving CBD plus THC achieved the predefined pain response criterion compared with 2/25 patients (8%) receiving CBD alone. The CBD + THC group also showed greater improvements in continuous pain VAS and sleep quality. Conclusions: Low-dose CBD did not yield meaningful pain relief. The addition of low-dose THC was associated with improvements in pain and sleep quality. These findings should be regarded as hypothesis-generating and require confirmation in blinded randomized controlled trials. Trial registration: European Union Clinical Trials Register, EudraCT 2017–004226-15, prospectively registered before enrolment of the first participant; Danish Medicines Agency 2018–010018.
- 31 August 2026
- Published by Springer Nature in Journal of Cannabis Research
Open AccessCannabidiol for chronic pain in rheumatoid arthritis and ankylosing spondylitis: a randomized, placebo-controlled trial with exploratory tetrahydrocannabinol add-on
Background: Persistent chronic pain remains a major unmet need in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS), even when inflammatory disease activity is low. Evidence for cannabinoid-based treatment in inflammatory rheumatic disease is limited. We investigated the efficacy and safety of low-dose cannabidiol (CBD) for chronic pain in RA and AS and explored the effects of adjunctive tetrahydrocannabinol (THC) in non-responders. Methods: In this multicentre, double-blind, randomized, placebo-controlled trial, 66 patients with RA or AS and persistent pain despite low inflammatory disease activity were randomized 1:1 to oral CBD or placebo for 12 weeks. The primary endpoint was a reduction of at least 20 points on the pain visual analogue scale (VAS) at week 12. After the blinded phase, non-responders entered a 12-week open-label phase: non-responders in the placebo group switched to CBD, while non-responders in the CBD group received add-on THC. Secondary outcomes included continuous pain VAS, sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI), cognitive performance assessed by the Trail Making Test (TMT) and Digit Symbol Substitution Test (DSST), disease activity measures, and safety. Results: At week 12, the primary endpoint was achieved by 9/32 patients (28%) receiving placebo and 3/30 patients (10%) receiving low-dose CBD. Low-dose CBD did not demonstrate superior pain relief compared with placebo and was associated with poorer sleep quality, while no significant between-group differences were observed for cognitive outcomes or inflammatory markers. In the exploratory open-label phase, 9/23 patients (39%) receiving CBD plus THC achieved the predefined pain response criterion compared with 2/25 patients (8%) receiving CBD alone. The CBD + THC group also showed greater improvements in continuous pain VAS and sleep quality. Conclusions: Low-dose CBD did not yield meaningful pain relief. The addition of low-dose THC was associated with improvements in pain and sleep quality. These findings should be regarded as hypothesis-generating and require confirmation in blinded randomized controlled trials. Trial registration: European Union Clinical Trials Register, EudraCT 2017–004226-15, prospectively registered before enrolment of the first participant; Danish Medicines Agency 2018–010018.
- 18 June 2026
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 22 (9) , 558-570
Lung disease in rheumatoid arthritis
Rheumatoid arthritis (RA) is a prevalent chronic systemic autoimmune inflammatory disease that primarily targets synovial joints and periarticular tissues. In RA, systemic inflammation has been associated with extra-articular manifestations, including pulmonary involvement, which are leading causes of reduced survival. Tobacco smoking is a well-established risk factor for anti-citrullinated protein antibody (ACPA)-positive RA and is also associated with chronic obstructive pulmonary disease, interstitial lung disease (ILD) and lung cancer, the prevalence of which is elevated in people with RA. Pulmonary manifestations such as airway obstructive disease, ILD and bronchiolitis affect a substantial proportion of people with RA. Screening for pulmonary disease, particularly ILD, is gaining emphasis, with high-resolution CT recommended based on risk factors including age, sex, antibody status and smoking. Despite advances in therapies to effectively manage joint inflammation, evidence-based treatments for RA-associated ILD remain limited. Chronic obstructive pulmonary disease and bronchiectasis in RA warrant more recognition owing to their effect on morbidity and mortality, and should be managed in accordance with current international treatment guidelines for these conditions. This Review summarizes the pathophysiology of lung involvement in RA, diagnostic challenges and evolving management strategies aimed at optimizing patient outcomes.
- 18 June 2026
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 22 (9) , 558-570
Lung disease in rheumatoid arthritis
Rheumatoid arthritis (RA) is a prevalent chronic systemic autoimmune inflammatory disease that primarily targets synovial joints and periarticular tissues. In RA, systemic inflammation has been associated with extra-articular manifestations, including pulmonary involvement, which are leading causes of reduced survival. Tobacco smoking is a well-established risk factor for anti-citrullinated protein antibody (ACPA)-positive RA and is also associated with chronic obstructive pulmonary disease, interstitial lung disease (ILD) and lung cancer, the prevalence of which is elevated in people with RA. Pulmonary manifestations such as airway obstructive disease, ILD and bronchiolitis affect a substantial proportion of people with RA. Screening for pulmonary disease, particularly ILD, is gaining emphasis, with high-resolution CT recommended based on risk factors including age, sex, antibody status and smoking. Despite advances in therapies to effectively manage joint inflammation, evidence-based treatments for RA-associated ILD remain limited. Chronic obstructive pulmonary disease and bronchiectasis in RA warrant more recognition owing to their effect on morbidity and mortality, and should be managed in accordance with current international treatment guidelines for these conditions. This Review summarizes the pathophysiology of lung involvement in RA, diagnostic challenges and evolving management strategies aimed at optimizing patient outcomes.
- Open Access
- 25 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (5)
Pericoronary adipose tissue as a biomarker of coronary atherosclerosis and cardiovascular risk in rheumatoid arthritis
Objectives: Pericoronary adipose tissue attenuation (PCATa) on computed tomography angiography reflects coronary artery inflammation and associated with cardiovascular risk beyond atherosclerosis in general patients. We aimed to evaluate the relationships between PCATa and coronary atherosclerosis burden, progression and cardiovascular risk in rheumatoid arthritis (RA). Methods: A total of 150 patients in a single-centre observational cohort underwent screening and surveillance coronary imaging 6.9 ±0.3 years later. PCATa around left anterior descending (LAD), left circumflex (LCx) and right coronary artery (RCA) were measured. Numbers of atherosclerotic segments (disease extent), plaque composition (noncalcified, low-density, mixed or calcified) and absolute volumes (mm3, plaque burden) were computed. Results: Mean (adjusted incidence rate ratio 1.21 [95% confidence interval 1.02–1.27]), LCx (1.20 [1.00–1.43]) and RCA-PCATa (1.22 [1.02–1.46] per standard deviation (SD) increase) associated with total plaque numbers and variably with plaque subtype extent and burden at baseline. Mean and artery-specific PCATa exhibited diverse associations with total, noncalcified, low-density and calcified plaque progression. Using artery-specific PCATa thresholds, mean (adjusted hazards ratio 0.10 [95% CI 0.02–0.56]), LCx (0.11 [95% CI 0.03–0.43]) and RCA-PCATa (0.15 [0.04–0.53] per SD increase) were linked to cardiovascular risk. RCA-PCATa threshold in particular increased risk estimate accuracy (ΔAUC = 0.066 [bias-corrected 95% CI 0.024–0.126], P = 0.005). Conclusion: Mean and artery-specific PCATa associated with the extent, burden and composition of coronary plaque and its progression in RA. Mean, LCx and RCA-PCATa were linked to cardiovascular events, and RCA-PCATa specifically optimized risk estimates beyond atherosclerosis, highlighting its potential utility as a predictive biomarker.
- 25 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (5)
Open AccessPericoronary adipose tissue as a biomarker of coronary atherosclerosis and cardiovascular risk in rheumatoid arthritis
Objectives: Pericoronary adipose tissue attenuation (PCATa) on computed tomography angiography reflects coronary artery inflammation and associated with cardiovascular risk beyond atherosclerosis in general patients. We aimed to evaluate the relationships between PCATa and coronary atherosclerosis burden, progression and cardiovascular risk in rheumatoid arthritis (RA). Methods: A total of 150 patients in a single-centre observational cohort underwent screening and surveillance coronary imaging 6.9 ±0.3 years later. PCATa around left anterior descending (LAD), left circumflex (LCx) and right coronary artery (RCA) were measured. Numbers of atherosclerotic segments (disease extent), plaque composition (noncalcified, low-density, mixed or calcified) and absolute volumes (mm3, plaque burden) were computed. Results: Mean (adjusted incidence rate ratio 1.21 [95% confidence interval 1.02–1.27]), LCx (1.20 [1.00–1.43]) and RCA-PCATa (1.22 [1.02–1.46] per standard deviation (SD) increase) associated with total plaque numbers and variably with plaque subtype extent and burden at baseline. Mean and artery-specific PCATa exhibited diverse associations with total, noncalcified, low-density and calcified plaque progression. Using artery-specific PCATa thresholds, mean (adjusted hazards ratio 0.10 [95% CI 0.02–0.56]), LCx (0.11 [95% CI 0.03–0.43]) and RCA-PCATa (0.15 [0.04–0.53] per SD increase) were linked to cardiovascular risk. RCA-PCATa threshold in particular increased risk estimate accuracy (ΔAUC = 0.066 [bias-corrected 95% CI 0.024–0.126], P = 0.005). Conclusion: Mean and artery-specific PCATa associated with the extent, burden and composition of coronary plaque and its progression in RA. Mean, LCx and RCA-PCATa were linked to cardiovascular events, and RCA-PCATa specifically optimized risk estimates beyond atherosclerosis, highlighting its potential utility as a predictive biomarker.
- 21 March 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (4)
Rheumatologist assessment in established polymyalgia rheumatica
Objectives: Patients with established polymyalgia rheumatica (PMR) are often referred from general practitioners (GPs) to rheumatologists. This single-centre cohort study examined the frequency, indications and diagnostic outcomes of patients with established PMR referred to a rheumatology outpatient clinic after initial diagnosis by GPs or rheumatologists in a hospital outpatient setting. Methods: This single-centre retrospective cohort study included patients with established PMR referred to a department of rheumatology (2018–2024). Data from patient records covered time of referral, PMR diagnosis, discharge, re-referral, and indication for and outcome of rheumatologist assessment of patients with established PMR. Symptoms and clinical findings were also documented. Results: Among 237 patients diagnosed by rheumatologists, 52/204 (26%) of discharged patients were re-referred. They had shorter time from diagnosis to discharge than those not re-referred (median: 41 days vs 230 days, P < 0.01). Referrals of the 98 patients diagnosed by GPs were more often prompted by uncertainty about their primary diagnosis of PMR (51% vs 14%, P < 0.01), and less frequently by relapse (27% vs 50%, P < 0.01) or recurrence (11% vs 31%, P < 0.01) compared with patients diagnosed by rheumatologists. The PMR diagnosis was less frequently maintained in patients diagnosed by GPs compared with patients diagnosed by rheumatologists (62% vs 83%, P < 0.05). Conclusion: Re-referral was common among patients with established PMR, and the risk increased with discharge shortly after PMR diagnosis. The diagnosis was revised in one-third of patients diagnosed by GPs, highlighting diagnostic challenges and supporting referral of individuals suspected of PMR consistent with current recommendations.
- 21 March 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (4)
Rheumatologist assessment in established polymyalgia rheumatica
Objectives: Patients with established polymyalgia rheumatica (PMR) are often referred from general practitioners (GPs) to rheumatologists. This single-centre cohort study examined the frequency, indications and diagnostic outcomes of patients with established PMR referred to a rheumatology outpatient clinic after initial diagnosis by GPs or rheumatologists in a hospital outpatient setting. Methods: This single-centre retrospective cohort study included patients with established PMR referred to a department of rheumatology (2018–2024). Data from patient records covered time of referral, PMR diagnosis, discharge, re-referral, and indication for and outcome of rheumatologist assessment of patients with established PMR. Symptoms and clinical findings were also documented. Results: Among 237 patients diagnosed by rheumatologists, 52/204 (26%) of discharged patients were re-referred. They had shorter time from diagnosis to discharge than those not re-referred (median: 41 days vs 230 days, P < 0.01). Referrals of the 98 patients diagnosed by GPs were more often prompted by uncertainty about their primary diagnosis of PMR (51% vs 14%, P < 0.01), and less frequently by relapse (27% vs 50%, P < 0.01) or recurrence (11% vs 31%, P < 0.01) compared with patients diagnosed by rheumatologists. The PMR diagnosis was less frequently maintained in patients diagnosed by GPs compared with patients diagnosed by rheumatologists (62% vs 83%, P < 0.05). Conclusion: Re-referral was common among patients with established PMR, and the risk increased with discharge shortly after PMR diagnosis. The diagnosis was revised in one-third of patients diagnosed by GPs, highlighting diagnostic challenges and supporting referral of individuals suspected of PMR consistent with current recommendations.